Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698848 · ClinicalTrials.gov registry record · Phase 1
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT06698848: Active Phase 1 study, sponsored by Massachusetts General Hospital.
NCT06698848 is a Phase 1 study that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06698848, a Phase 1 study, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression and associated suicidality but its exact mechanism of remains uncertain. This study will use a novel approach to elucidate KET's effects on the molecular/ gene expression pathways in living neurons obtained from the olfactory epithelium and correlate the changes to rapid improvement in depression via changes in the brain connectome. The study will identify the molecular targets and pathways involved in KET'S mechanism of rapid clinical action and pave the way for development of novel, more efficacious, and safer therapeutic agents.
Interventions
- DRUG ketamin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698848
The ClinicalTrials.gov registry entry for NCT06698848 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ketamin is the first listed.
NCT06698848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06698848 about?
NCT06698848 is a clinical study titled "Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome". Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression and associated suicidality but its exact mechanism of remains uncertain. This study will use a novel approach to elucidate KET's effects on the molecular/ gene expression pathways in ...
What is the current status of trial NCT06698848?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-01-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT06698848?
The interventions under investigation include: ketamin (DRUG).
Who is sponsoring clinical trial NCT06698848?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.